People: Novo Nordisk A/S (NVONy.F)


NVONy.F on Frankfurt Stock Exchange

122.10EUR
18 Jun 2013
Price Change (% chg)

€0.59 (+0.49%)
Prev Close
€130.76
Open
€121.00
Day's High
€122.10
Day's Low
€120.91
Volume
60
Avg. Vol
679
52-wk High
€145.78
52-wk Low
€108.37

Search Stocks

Summary

Name Age Since Current Position

Goran Ando

 64 2013 Chairman of the Board

Lars Rebien Soerensen

 58 2000 President, Chief Executive Officer

Jeppe Christiansen

 2013 Vice Chairman of the Board

Jesper Brandgaard

 49 2000 Chief Financial Officer, Executive Vice President

Kare Schultz

 51 2002 Chief Operating Officer, Executive Vice President

Lars Joergensen

 46 2013 Executive Vice President, Chief Information Officer

Mads Krogsgaard Thomsen

 52 2000 Chief Science Officer, Executive Vice President

Jakob Riis

 47 2013 Executive Vice President, Marketing & Medical Affairs

Lise Kingo

 51 2002 Executive Vice President, Chief of Staffs

Henrik Gurtler

 59 2005 Director

Ulrik Hjulmand-Lassen

 51 2010 Director, Employee Representative

Anne Kverneland

 56 2000 Director, Employee Representative

Stig Stroebaek

 49 1998 Director, Employee Representative

Soeren Thuesen Pedersen

 48 2006 Director, Employee Representative

Bruno Angelici

 66 2011 Independent Director

Liz Hewitt

 56 2012 Independent Director

Thomas Koestler

 61 2011 Independent Director

Hannu Ryopponen

 61 2009 Independent Director

Kasper Roseeuw Poulsen

 Head of Investor Relations
» Insider Trading

Biographies

Name Description

Goran Ando

 Dr. Goran A. Ando has served as Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He was Vice Chairman of the Company's Board from March 8, 2006 until March 20, 2013, and he has been Member of the Board of the Company since March 9, 2005. Dr. Ando was Chief Executive Officer (CEO) of Celltech Group plc in the United Kingdom until 2004. He joined Celltech from Pharmacia (currently Pfizer) where he was Executive Vice President and President of Research and Development with additional responsibilities for manufacturing, Information Technology, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, he was Medical Director, moving to Deputy Research and Development Director, and then Research and Development Director of Glaxo Group in the United Kingdom. He was also Member of the Glaxo Group Executive Committee. He is Specialist in General Medicine and Founding Fellow of the American College of Rheumatology in the United States. He serves as Chairman of the Board of Directors of Symphogen A/S and as Member of the Boards of Novo A/S and Molecular Partners AG. He also serves as Senior Advisor to Essex Woodlands Health Ventures Ltd. in the United Kingdom and as Member of the Scientific Advisory Board of Bausch & Lomb, the United States. He has qualifications and executive background within the international pharmaceutical industry. He qualified as Medical Doctor at Linkopings Universitet (the University of Linkoping) in 1973, and as Specialist in General Medicine at the same institution in 1978.

Lars Rebien Soerensen

 Mr. Lars Rebien Soerensen has been President and Chief Executive Officer (CEO) at Novo Nordisk A/S since November 2000. He joined the Company's Enzymes Marketing in 1982. Over the years, he has been stationed in several countries, including the Middle East and the United States. He was appointed Member of Corporate Management in May 1994, and was given responsibility for Health Care within Corporate Management in December 1994. He is Member of the Boards of Directors of Danmarks Nationalbank and Thermo Fisher Scientific Inc., as well as Member of the Bertelsmann AG Supervisory Board in Germany. He received the French award Chevalier de l'Ordre National de la Legion d'Honneur in 2005. Since October 2007, he has been Adjunct Professor at the Faculty of Life Sciences of Koebenhavns Universitet (the University of Copenhagen). He holds a Master of Science degree in Forestry from Koebenhavns Universitet from 1981, and a Bachelor of Science degree in International Economics from Copenhagen Business School from 1983.

Jeppe Christiansen

Jesper Brandgaard

 Mr. Jesper Brandgaard has been Chief Financial Officer (CFO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1999 as Senior Vice President of Corporate Finance. He serves as Chairman of the Boards of Directors at SimCorp A/S and NNIT A/S, both in Denmark. He holds a Master of Science degree in Economics and Auditing from 1990, as well as a Master of Business Administration degree from 1995, both from the Copenhagen Business School in Denmark.

Kare Schultz

 Mr. Kaare Schultz has been Chief Operating Officer (COO) and Executive Vice President at Novo Nordisk A/S since March 2002. He joined the Company in 1989 as Economist in Health Care, Economy and Planning. In November 2000, he was appointed Chief of Staffs. He also serves as Member of the Board of Directors at LEGO A/S and as Chairman of the Board of Directors at Royal Unibrew A/S. Mr. Schultz holds a Master of Science degree in Economics from Koebenhavns Universitet (the University of Copenhagen) from 1987.

Lars Joergensen

 Mr. Lars Fruergaard Joergensen has served as Executive Vice President, Chief Information Officer of Novo Nordisk A/S since January 31, 2013. He joined Novo Nordisk in 1991 as Economist in Health Care, Economy and Planning and has over the years completed overseas postings in the United States and Japan. In 2004, he was appointed Senior Vice President for IT (Information Technology) and Corporate Development. He represents Novo Nordisk as Chairman of the Board of Harno Invest A/S, Denmark and as Member of the Supervisory Board of Innate Pharma S.A., France. He is also Vice Chairman of the Board of NNE Pharmaplan A/S and Member of the Board of NNIT A/S, both in Denmark. He holds a Master of Science degree in Finance and Business Administration from Aarhus School of Business, Aarhus University (Aarhus Universitet), Denmark, from 1991.

Mads Krogsgaard Thomsen

 Dr. Mads Krogsgaard Thomsen has been Chief Science Officer (CSO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1991 and has been Head of Growth Hormone Research, Diabetes Research & Development, Global Drug Discovery. He sits on the Editorial Boards of international journals and is Member of the Board of Directors of University of Copenhagen, Denmark. He is former President of the National Academy of Technical Sciences (ATV). He obtained a DMV degree in Veterinary Medicine from Koebenhavns Universitet in 1986, where he also obtained a Doctorate of Philosophy degree in 1989, and a Doctorate of Science degree in 1991. In 2000 he became Adjunct Professor of Pharmacology at the Royal Veterinary and Agricultural University (currently the Faculty of Health and Medical Sciences of the University of Copenhagen), Denmark.

Jakob Riis

 Mr. Jakob Riis has served as Executive Vice President, Marketing & Medical Affairs of Novo Nordisk A/S since January 31, 2013. He joined Novo Nordisk in 1996. From 2001 through 2005, he worked first in the United States sales force and then as Head of Marketing in Japan. In 2005, he was appointed Senior Vice President for International Marketing. He is also Chairman of the Board of Copenhagen Institute of Interaction Design. He holds a Master of Science degree in Forestry from the Royal Veterinary and Agricultural University, Denmark (currently the Faculty of Science of the University of Copenhagen -Koebenhavns Univesitet) from 1992, where he also obtained a Doctorate of Philosophy degree in 1998.

Lise Kingo

 Ms. Lise Kingo has been Chief of Staffs (COS) and Executive Vice President at Novo Nordisk A/S since March 2002. She has global responsibility for Corporate Relations. She joined the Company in 1988 and worked over the years to build up the Company’s Triple Bottom Line approach. In 1999, she was appointed Senior Vice President, Stakeholder Relations. She serves as Chairman of the Board of Directors at Steno Diabetes Center A/S and is Chairman of the Danish Council on Corporate Social Responsibility. She is also Adjunct Professor at the Medical Faculty at Vrije Universiteit in Amsterdam, the Netherlands. Ms. Kingo holds a Bachelor of Arts degree in Religions and Ancient Greek Art from Aarhus Universitet from 1986, a Bachelor's degree in Marketing and Economics from the Copenhagen Business School from 1991, and a Master of Science degree with honors in Responsibility and Business Practice from University of Bath in the United Kingdom from 2000.

Henrik Gurtler

 Mr. Henrik Gurtler has served as Member of the Board of Directors of Novo Nordisk A/S since March 9, 2005. He has been President and Chief Executive Officer (CEO) of Novo A/S in Denmark since 2000. He was employed by Novo Industri A/S in Denmark as Research and Development Chemist in the Enzymes Division in 1977. After a number of years in various Specialist and Managerial positions within this area, he was appointed Corporate Vice President of Human Resource Development at Novo Nordisk A/S in 1991, and in 1993 he was appointed Corporate Vice President of Health Care Production. From 1996 to 2000, he was Member of Corporate Management of Novo Nordisk A/S with special responsibility for Corporate Staffs. He is Chairman of the Boards of Novozymes A/S, Copenhagen Airports A/S and COWI Holding A/S, all in Denmark. He has knowledge of the international biotech industry. He obtained a Master of Science degree in Chemical Engineering from Danmarks Tekniske Universitet (the Technical University of Denmark) in 1976.

Ulrik Hjulmand-Lassen

 Mr. Ulrik Hjulmand-Lassen has been Employee Representative on the Board of Directors at Novo Nordisk A/S since March 2010. He holds a Bachelor of Science degree from Danmarks Tekniske Universitet from 1985. He was trained as ISO 9001 Lead Auditor in 2006 and in MCSA/IT Security in 2009, as well as CISM in 2011. He joined the Company in 2002 and works as a Senior IT (Information Technology) Quality Advisor in IT Governance.

Anne Kverneland

 Ms. Anne Marie Kverneland has been Employee Representative on the Board of Directors at Novo Nordisk A/S since November 2000. She joined the Company in July 1981 as Laboratory Technician. She currently works as Shop Steward. She has a degree in Medical Laboratory Technology from Koebenhavns Universitet (Copenhagen University Hospital) in Denmark from 1980.

Stig Stroebaek

 Mr. Stig Stroebaek has been Employee Representative on the Board of Directors at Novo Nordisk A/S since 1998. He joined the Company in 1992 as Electrician. He works as Shop Steward in the Company. He has been Member of the Board of the Novo Nordisk Foundation since 1998. Mr. Stroebaek holds a diploma in Electrical Engineering and a diploma in further training for Members of the Boards of Directors from the Danish Employees’ Capital Pension Fund (LD) from 2003.

Soeren Thuesen Pedersen

 Mr. Soeren Thuesen Pedersen has been Employee Representative on the Board of Directors at Novo Nordisk A/S since March 2006. He joined the Company in January 1994. He works as External Affairs Director in Quality Intelligence in the Company. He has been Member of the Board of Directors of the Novo Nordisk Foundation since 2002. He graduated with a Bachelor of Science degree in Chemical Engineering from Danmarks Ingenioerakademi, currently part of Danmarks Tekniske Univeristet, in 1988.

Bruno Angelici

 Mr. Bruno Angelici has served as Independent Member of the Board of Directors of Novo Nordisk A/S since March 23, 2011. He was Executive Vice President of AstraZeneca, with P&L responsibility for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa from 2001 until 2009. In 1998, he was appointed President of Zeneca, Japan. Previously, from 1989, he was President of Zeneca, France, having joined from Baxter International, where he held various management positions from 1978 to 1989. He is Member of the Board of Directors of Smiths Group plc, the United Kingdom and Member of the Supervisory Board of Wolters Kluwer, the Netherlands. Additionally, he is Member of the Global Advisory Board at Takeda Pharmaceutical Company Limited, Japan. He has global experience with two companies in the fields of pharmaceuticals and medical devices, as well as knowledge of strategy, sales, marketing and governance of main companies. He holds a Bachelor of Arts degree in Business Administration from Ecole Superieure de Commerce Reims from 1971. He graduated in Law from Universite de Reims Champagne Ardenne in 1973. In addition, he has a Master of Business Administration degree from Kellogg School of Management at NorthWestern University from 1978 and an AMP from Harvard Business School from 1993, both in the United States.

Liz Hewitt

 Ms. Liz Hewitt has been Independent Member of the Board of Directors of Novo Nordisk A/S since March 21, 2012. She has been Member of the Company's Audit Committee since March 2012. She was previously Group Director Corporate Affairs for Smith & Nephew plc from 2004 until 2011 and was involved at a senior level in all aspects of the business, including membership of Risk Committee of the company. From 1986 until 2004, she held a number of roles at 3i Group plc, from investing and syndicating private equity transactions to running the internal consultancy team, culminating her role as Director Corporate Affairs, when she was a Member of Risk Committee and a Trustee of the 3i Charitable Foundation. She qualified with Andersen & Co and also worked as a private equity investor for Citicorp Venture Capital (currently CVC) and Gartmore Investment Management Ltd. She serves as Member of the Board and Chairman of the Audit Committee of Synergy Health plc. She is also External Member of the Audit Committee of the House of Lords, the United Kingdom. She has experience within the field of medical devices, financial knowledge and knowledge of how international companies operate. She holds a Bachelor of Science degree with honors in Economics from University College London from 1977 and became Chartered Accountant FCA from the Institute of Chartered Accountants in 1982.

Thomas Koestler

 Dr. Thomas (Tom) Paul Koestler, Ph.D. has served as Independent Member of the Board of Directors of Novo Nordisk A/S since March 23, 2011. He is an Executive with Vatera Holdings LLC, the United States. From 2003 to 2009, he was Executive Vice President, and from 2006 President of Schering-Plough Research Institute. Before joining Schering-Plough Research Institute, he was Senior Vice President and Global Head of Regulatory Affairs of Pharmacia Corporation, from 2001. From 1996 to 2001, he was Vice President, later Senior Vice President in Novartis Pharmaceuticals within Regulatory Affairs. From 1982 to 1996, he held various management positions within Regulatory Affairs and Clinical Safety in Sandoz Pharmaceutical Corporation, Johnson & Johnson Bristol-Myers Squibb, and Smith Kline French Labs. He is a Member of the Board of Directors of Momenta Pharmaceuticals Inc., ImmusanT Inc., Arisaph Pharmaceuticals Inc., Rib-X Pharmaceuticals Inc., and Pearl Therapeutics Inc. He is also Chairman of the Scientific Advisory Board of Bausch & Lomb. He has Research and Development knowledge, both generally and within the field of regulatory affairs. He has know-how about the pharmaceutical industry in general and how international corporations operate. He has additional knowledge of the United States market. He holds a Bachelor of Science degree in Biology from Daemen College from 1975, and a Doctorate of Philosophy degree in Medicine and Pathology from the Roswell Park Memorial Institute, part of State University of New York, from 1982.

Hannu Ryopponen

 Mr. Hannu Ryopponen has served as Independent Member of the Board of Directors at Novo Nordisk A/S since March 18, 2009. He has also been Chairman of the Company's Audit Committee since March 2012. He was Chief Financial Officer (CFO) and Deputy Chief Executive Officer (CEO) of Stora Enso Oyj in Finland until 2009. Before that, he was CFO and Executive in Royal Ahold in the Netherlands from 2003 to 2005, and served on the Board of Directors of the ICA Group in Sweden, including the Chairmanship of the Audit Committee. From 1999 to 2003, Mr. Ryopponen was Finance Director of Industri Kapital Group in the United Kingdom. He served as CFO of the IKEA Group in Denmark from 1985 to 1998, including a position as Deputy CEO of IKANO Asset Management from 1998 to 1999. From 1977 to 1985, he held various Management positions at Chemical Bank in the United States and the United Kingdom, as well as at Alfa Laval in the United States and Sweden. He is Chairman of Private equity funds Altor 2003 GP Limited, Altor Fund II GP Limited and Altor III GP Limited, as well as Chairman of the Boards of Hakon Invest AB and BillerudKorsnas AB. He is also Member of the Boards of Amer Sports Oyj and the private equity fund Value Creation Investments Limited. Mr. Ryopponen is also Chairman of the Audit Committee of Amer Sports Oyj. He has international executive background and understanding of managing finance operations in global organizations, in particular in relation to accounting, financial and capital markets issues, but also experience in private equity and mergers & acquisitions. He holds a Bachelor of Arts degree in Business Administration from Hanken - Svenska handelshogskolan in Helsinki, Finland, from 1976.

Kasper Roseeuw Poulsen

Basic Compensation

Name Fiscal Year Total

Goran Ando

 1,100,000

Lars Rebien Soerensen

 14,400,000

Jeppe Christiansen

 --

Jesper Brandgaard

 8,300,000

Kare Schultz

 8,600,000

Lars Joergensen

 --

Mads Krogsgaard Thomsen

 8,300,000

Jakob Riis

 --

Lise Kingo

 7,100,000

Henrik Gurtler

 500,000

Ulrik Hjulmand-Lassen

 500,000

Anne Kverneland

 500,000

Stig Stroebaek

 500,000

Soeren Thuesen Pedersen

 500,000

Bruno Angelici

 600,000

Liz Hewitt

 700,000

Thomas Koestler

 800,000

Hannu Ryopponen

 1,000,000

Kasper Roseeuw Poulsen

 --
As Of 30 Dec 2012

Insider Trading

» Full list on Insider Trading
Search Stocks